This primary purpose of this study is to evaluate the safety, tolerability, and pharmacokinetic properties of multiple ascending doses of ATN-103 administered subcutaneously (below the skin) to Japanese subjects with active rheumatoid arthritis and on a stable background of methotrexate. Some subjects will receive ATN-103 while other subjects will receive a placebo.
Read more: http://www.clinicaltrials.gov/ct2/show/NCT01007175?cond=%22Arthritis%22&lup_s=08/23/2013&lup_d=30
